跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 103,421 条关于
“ESR1-mutant metastatic breast cancer”
全部
103,421
临床试验
84,512
药物
2,424
机构
1,175
资讯
15,310
去年
EMERALD Trial Data Reveals Duration of Prior CDK4/6 Inhibitor Therapy as Key Predictor for Elacestrant Success in ESR1-Mutant Breast Cancer
9个月前
Athira Pharma Secures $236 Million Financing and Exclusive Rights to Lasofoxifene for ESR1-Mutant Metastatic Breast Cancer
昨天
FDA Grants Accelerated Approval to AstraZeneca's Camizestrant (Etcamah) for ESR1-Mutant Metastatic Breast Cancer
2年前
Novel PROTAC Vepdegestrant Shows Promise for ESR1-Mutant Breast Cancer in Phase 2 Trial
去年
ESR1 Mutation Presence, Not Frequency, Should Guide Metastatic Breast Cancer Treatment Decisions
去年
Real-World Data Suggests Elacestrant Offers Similar or Improved Outcomes in Advanced Breast Cancer
3个月前
UAE Becomes First Country Worldwide to Approve AstraZeneca's Oral SERD Camizestrant for ESR1-Mutant Breast Cancer
上个月
Evexta Bio and Roche Ink Clinical Collaboration to Evaluate Rupitasertib Plus Giredestrant in ESR1-Mutated Metastatic Breast Cancer
4个月前
FDA Approves First PROTAC Drug VEPPANU for ESR1-Mutated Breast Cancer
去年
ESR1 Mutations in Breast Cancer: Emerging Biomarker Reshapes Treatment Strategies
第 1 页，共 1531 页
上一页
下一页
